BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlu-Aß antibody programme effective after antitrust clearance and closing: Stockholm, Sweden Saturday, Fe ...

Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics ...

The company’s 2024 acquisition of Aliada Therapeutics includes the latter’s lead investigational asset ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development ...

The Boston biotech said the platform had enabled the development of ALIA-1758 – an anti-pyroglutamate amyloid beta (Aβ3pE) antibody, which it says is a 'potential best-in-class therapy for ...

BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are highly prone to aggregate, ...